Cholesterol efflux capacity: An introduction for clinicians

American Heart Journal

Volumn 180, Issue , 2016, Pages 54-63

  Anastasius, Malcolm ^a   Kockx, Maaike ^a   Jessup, Wendy ^a   Sullivan, David ^b   Rye, Kerry Anne ^c   Kritharides, Leonard ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; CHOLESTEROL;

ACUTE CORONARY SYNDROME; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL EFFLUX CAPACITY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIABETES MELLITUS; DIET; DRUG THERAPY; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIPID COMPOSITION; PRIORITY JOURNAL; REVIEW; SERUM EFFLUX CAPACITY; WEIGHT REDUCTION; BLOOD; CELL CULTURE; IN VITRO STUDY; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

AUTOIMMUNE DISEASES; BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL, HDL; DIABETES MELLITUS; HUMANS; IN VITRO TECHNIQUES;

EID: 84979966793     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.07.005     Document Type: Review

References (81)

1. 1. Gordon, T, Castelli, W, Hjortland, M, High density lipoprotein as a protective factor against coronary artery disease. The Framingham Study. Am J Med 62 (1977), 707–714.
2. 2. Baigent, C, Blackwell, L, Emberson, J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
3. 3. Badimon, J, Badimon, L, Galvez, A, et al. High density lipoprotein plasma fractions inhibit aortic fatty streak lesions in cholesterol-fed rabbits. Lab Invest 60 (1989), 455–461.
4. 4. Rubin, E, Krauss, R, Spangler, E, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353 (1991), 265–267.
5. 5. Tangirala, R, Tsukamoto, K, Chun, S, et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100 (1999), 1816–1822.
6. 6. Mortensen, M, Afzal, S, Nordestgaard, B, et al. The high-density lipoprotein–adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30 824 Europeans: the Copenhagen General Population Study. Eur Heart J 36 (2015), 2446–2453.
7. 7. Taskinen, M, Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46 (2003), 733–749.
8. 8. Jorgensen, A, Frikke-Schmidt, R, Nordestgaard, B, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 37 (2014), 32–41.
9. 9. Voight, B, Peloso, G, Orho-Melander, M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380 (2012), 572–580.
10. 10. Hasse, C, Tybjaerg-Hansen, A, Grande, P, et al. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metabol 95 (2010), E500–E510.
11. 11. Hasse, C, Tybjaerg-Hansen, A, Qayyum, A, et al. LCAT, HDL cholesterol and ischemic cardiovascular disease: a mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metabol 97 (2012), E248–E256.
12. 12. Barter, P, Caulfield, M, Eriksson, M, Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007), 2110–2122.
13. 13. Investigators TAH, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
14. 14. Schwartz, G, Olsson, A, Abt, M, Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367 (2012), 2089–2099.
15. 15. Rosensen, R, Brewer, H, Davidson, W, Cholesterol efflux and atheroprotection, advancing the concept of reverse cholesterol transport. Circulation 125 (2012), 1905–1919.
16. 16. Heinecke, J, A new era for quantifying HDL and cardiovascular risk?. Nature 18 (2012), 1346–1347.
17. 17. Zhang, Y, Zanotti, I, Reilly, M, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108 (2003), 661–663.
18. 18. Eriksson, M, Carlson, L, Miettinen, T, et al. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I potential reverse cholesterol transport in humans. Circulation 100 (1999), 594–598.
19. 19. Alam, K, Meidell, R, Spady, D, Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem 276 (2001), 15641–15649.
20. 20. de la Llera, MM, Atger, V, Paul, J, et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux: relationships between serum components and efflux, esterification, and transfer. Arterioscler Thromb 14 (1994), 1056–1065.
21. 21. Rothblat, G, Phillips, M, Mechanism of cholesterol efflux from cells: effects of acceptor structure and concentration. J Biol Chem 257 (1982), 4775–4782.
22. 22. Phillips, M, Molecular mechanisms of cellular cholesterol efflux. J Biol Chem 289 (2014), 24020–24029.
23. 23. Rohatgi, A, High-Density lipoprotein function measurement in human studies: focus on cholesterol efflux capacity. Prog Cardiovasc Dis 58 (2015), 32–40.
24. 24. Adorni, M, Zimetti, F, Billheimer, J, et al. The role of different pathways in the release of cholesterol from macrophages. J Lipid Res 48 (2007), 2453–2462.
25. 25. Du, X, Kim, M, Hou, L, et al. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res 116 (2015), 1133–1142.
26. 26. Out, R, Jessup, W, Le Goff, W, et al. Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Circ Res 102 (2008), 113–120.
27. 27. Larrede, S, Quinn, C, Jessup, W, et al. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol 29 (2009), 1930–1936.
28. 28. Remaley, A, Schumacher, U, Stonik, J, et al. Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. Arterioscler Thromb Vasc Biol 17 (1997), 1813–1821.
29. 29. van Dam, M, de Groot, E, Clee, S, et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 359 (2002), 37–41.
30. 30. de la Llera-Moya, M, Drazul-Schrader, D, Asztalos, B, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 30 (2010), 796–801.
31. 31. Khera, A, Cuchel, M, de la Llera, MM, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364 (2011), 127–135.
32. 32. Li, X, Tang, W, Mosior, M, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 33 (2013), 1696–1705.
33. 33. Rohatgi, A, Khera, A, Berry, J, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371 (2014), 2383–2393.
34. 34. Saleheen, D, Scott, R, Javad, S, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-controlstudy. Lancet Diabetes Endocrinol 3 (2015), 507–513.
35. 35. Dahabreh, I, Kent, D, Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA 305 (2011), 822–823.
36. 36. Mody, P, Joshi, P, Khera, A, et al. Beyond coronary calcification, family history, and C-reactive protein. Cholesterol efflux capacity and cardiovascular risk prediction. J Am Coll Cardiol 67 (2016), 2480–2487.
37. 37. Kontush, A, Chapman, M, Antiatherogenic small, dense HDL—guardian angel of the arterial wall?. Nat Clin Pract Cardiovasc Med 3 (2006), 144–153.
38. 38. Jeyarajah, E, Cromwell, W, Otvos, J, Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26 (2006), 847–870.
39. 39. Caulfield, M, Li, S, Lee, G, et al. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem 54 (2008), 1307–1316.
40. 40. Rached, F, Lhomme, M, Camont, L, et al. Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A. Biochim Biophys Acta 2015 (1851), 1254–1261.
41. 41. Tan, H, Tai, E, Sviridov, D, et al. Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus. J Clin Lipidol 5 (2011), 467–473.
42. 42. Cavallero, E, Brites, F, Delfy, B, Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles. Arterioscler Thromb Vasc Biol 15 (1995), 2130–2135.
43. 43. Syvanne, M, Castro, G, Dengremont, C, et al. Cholesterol eflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis 127 (1996), 245–253.
44. 44. Igau, B, Castro, G, Clavey, V, In vivo glucosylated LpA-I subfraction. Evidence for structural and functional alterations. Arterioscler Thromb Vasc Biol 17 (1997), 2830–2836.
45. 45. Rosensen, R, Brewer, H, Ansell, B, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 13 (2016), 48–60.
46. 46. de Vries, R, Groen, A, Perton, F, et al. Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification., 196, 2008, 733–741.
47. 47. Yassine, H, Belopolskaya, A, Schall, C, et al. Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes. Metabolism 63 (2014), 727–734.
48. 48. Solomon, D, Karlson, E, Rimm, E, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107 (2003), 1303–1307.
49. 49. Wolfe, F, Freundlich, B, Straus, W, Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30 (2003), 36–40.
50. 50. Shoenfeld, Y, Gerli, R, Doria, A, Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112 (2005), 3337–3347.
51. 51. Ronda, N, Favari, E, Borghi, M, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis, 2013, 1–7.
52. 52. Hua, X, Su, J, Svenungsson, E, Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease. Scand J Rheumatol 38 (2009), 184–189.
53. 53. Juarez-Rojas, J, Medina-Urrutia, A, Posadas-Sanchez, R, High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus. Lupus 17 (2008), 981–987.
54. 54. Fournier, N, Paul, J, Atger, V, et al. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol 17 (1997), 2685–2691.
55. 55. Agarwala, A, Rodrigues, A, Risman, M, et al. High-density lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease. Arterioscler Thromb Vasc Biol 35 (2015), 1–5.
56. 56. Soutar, A, Naoumova, R, Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 4 (2006), 214–225.
57. 57. Brown, M, Goldstein, J, A receptor-mediated pathway for cholesterol homeostasis. Science 232 (1986), 34–47.
58. 58. Bellanger, N, Orsoni, A, Julia, Z, et al. Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 31 (2011), 1675–1681.
59. 59. Mehta, N, Azfar, R, Shin, D, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31 (2010), 1000–1006.
60. 60. Gelfand, J, Neimann, A, Shin, D, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006), 1735–1741.
61. 61. Salahuddin, T, Natarajan, B, Playford, M, et al. Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. Eur Heart J 36 (2015), 2662–2665.
62. 62. Brites, F, Verona, J, De Geitere, C, et al. Enhanced cholesterol efflux promotion in well-trained soccer players. Metabolism 53 (2004), 1262–1267.
63. 63. Koba, S, Ayaori, M, Uto-Kondo, H, et al. Beneficial effects of exercise-based cardiac rehabilitation on high-density lipoprotein-mediated cholesterol efflux capacity in patients with acute coronary syndrome. J Atheroscler Thromb 23 (2016), 1–13.
64. 64. Sola, R, Motta, C, Maille, M, et al. Dietary monounsaturated fatty acids enhance cholesterol efflux from human fibroblasts. Relation to fluidity, phospholipid fatty acid composition, overall composition and size of HDL3. Arterioscler Thromb Vasc Biol 13 (1993), 958–966.
65. 65. Montoya, M, Porres, A, Serrano, S, et al. Fatty acid saturation of the diet and plasma lipid concentrations, lipoprotein particle concentrations, and cholesterol efflux capacity. Am J Clin Nutr 75 (2002), 484–491.
66. 66. Hernaz, A, Fernandez-Castillejo, S, Farras, M, et al. Olive oil polyphenols enhance high-density lipoprotein function in humans. A randomized controlled trial. Arterioscler Thromb Vasc Biol 34 (2014), 2115–2119.
67. 67. Osto, E, Doytcheva, P, Corteville, C, et al. Rapid and body weight–independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass role of glucagon-like peptide-1. Circulation 131 (2015), 871–881.
68. 68. Bornfeldt, K, Tabas, I, Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 14 (2011), 575–585.
69. 69. Zimetti, F, Weibel, G, Duong, M, et al. Measurement of cholesterol bidirectional flux between cells and lipoproteins. J Lipid Res 47 (2006), 605–613.
70. 70. Rhainds, D, Renaud, J, Boule, M, et al. Abstract 17232: comparison of methods for the measurement of cholesterol efflux capacity of plasma HDL with J774 mouse macrophages reveals superiority of the radioactive cholesterol method over the BODIPY-cholesterol-2 method. Circulation, 132, 2015, A17232.
71. 71. Cignarella, A, Engel, T, von Eckardstein, A, et al. Pharmacological regulation of cholesterol efflux in human monocyte–derived macrophages in the absence of exogenous cholesterol acceptors. Atherosclerosis 179 (2005), 229–236.
72. 72. Joseph, S, McKilligin, E, Pei, L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 99 (2002), 7604–7609.
73. 73. Grefhorst, A, Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 277 (2002), 34182–34190.
74. 74. Chinetti, G, Lestavel, S, Bocher, V, et al. PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 (2001), 53–58.
75. 75. Ozasa, H, Ayaori, M, Iizuka, M, et al. Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPAR/LXR pathway: findings from in vitro and ex vivo studies. Atherosclerosis 219 (2011), 141–150.
76. 76. Franceschini, G, Calabresi, L, Colombo, C, et al. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 195 (2007), 385–391.
77. 77. Khera, A, Millar, J, Ruotolo, G, et al. Potent peroxisome proliferator–activated receptor-αagonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J, 1-3, 2015.
78. 78. Ormseth, M, Bridges, S, Curtis, J, et al. Effect of drug therapy on net cholesterol efflux capacity of HDL-enriched serum in rheumatoid arthritis [abstract]. Arthritis Rheum, 67(Suppl. 10), 2015.
79. 79. Nicholls, S, Ruotolo, G, Brewer, H, et al. Cholesterol efflux capacity and pre–beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib. J Am Coll Cardiol 66 (2015), 2201–2210.
80. 80. Nicholls S. Evacetrapib does not reduce major adverse cardiovascular events. Joint ACC/JAMA Late-Breaking Clinical Trials. Presented at: American College of Cardiology Scientific Session; April 2–4, 2016; Chicago.
81. 81. Havingh, G, Kastelein, J, van Deventer, S, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 386 (2015), 452–460.